Table 4.
Main Effects for Randomized Treatment Components | |||||||||
---|---|---|---|---|---|---|---|---|---|
Intervention Not Used | Intervention Used | Relative Difference between Groups | |||||||
Treatment Component | Assessment | Adjusted Mean (97.5% CI) | Change from 1-week | p value | Adjusted Mean (97.5% CI) | Change from 1-week | p value | Estimated relative difference 97.5% CI | p value |
SMT | 4 weeks | 3.28 (2.91, 3.64) | −0.75 (−1.09, −0.42) | <.001 | 3.13 (2.76, 3.51) | −0.90 (−1.24, −0.56) | <.001 | −0.14 (−0.60, 0.32) | 0.48 |
12 weeks | 3.02 (2.61, 3.42) | −1.02 (−1.39, −0.64) | <.001 | 3.10 (2.69, 3.51) | −0.93 (−1.32, −0.55) | <.001 | 0.08 (−0.44, 0.61) | 0.72 | |
ACTex | 4 weeks | 3.29 (2.92, 3.66) | −0.75 (−1.08, −0.41) | <.001 | 3.13 (2.76, 3.49) | −0.91 (−1.24, −0.57) | <.001 | −0.16 (−0.62, 0.30) | 0.43 |
12 weeks | 3.15 (2.74, 3.56) | −0.88 (−1.27, −0.5) | <.001 | 2.96 (2.56, 3.37) | −1.07 (−1.44, −0.69) | <.001 | −0.19 (−0.71, 0.33) | 0.42 | |
MOBex | 4 weeks | 3.43 (3.06, 3.81) | −0.60 (−0.94, −0.26) | <.001 | 2.98 (2.61, 3.34) | −1.05 (−1.39, −0.72) | <0.01 | −0.46 (−0.92, 0.0) | 0.03 |
12 weeks | 3.15 (2.74, 3.56) | −0.88 (−1.27, −0.5) | <.001 | 2.97 (2.56, 3.37) | −1.07 (−1.44, −0.69) | <0.01 | −0.18 (−0.70, 0.34) | 0.44 |
Mean values are adjusted for 1-week value of the pain intensity outcome measure and study site. P values refer to change from 1-week values.